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Background: Clinical specimens undergoing diagnostic molecular pathology testing are fixed in formalin due to
the necessity for detailed morphological assessment. However, formalin fixation can cause major issues with
molecular testing, as it causes DNA damage such as fragmentation and non-reproducible sequencing artefacts after
PCR amplification. In the context of massively parallel sequencing (MPS), distinguishing true low frequency variants
from sequencing artefacts remains challenging. The prevalence of formalin-induced DNA damage and its impact on
molecular testing and clinical genomics remains poorly understood.
Methods: The Cancer 2015 study is a population-based cancer cohort used to assess the feasibility of
mutational screening using MPS in cancer patients from Victoria, Australia. While blocks were formalin-fixed and
paraffin-embedded in different anatomical pathology laboratories, they were centrally extracted for DNA utilising
the same protocol, and run through the same MPS platform (Illumina TruSeq Amplicon Cancer Panel). The
sequencing artefacts in the 1-10% and the 10-25% allele frequency ranges were assessed in 488 formalin-fixed
tumours from the pilot phase of the Cancer 2015 cohort. All blocks were less than 2.5 years of age (mean 93 days).
Results: Consistent with the signature of DNA damage due to formalin fixation, many formalin-fixed samples
displayed disproportionate levels of C>T/G>A changes in the 1-10% allele frequency range. Artefacts were less
apparent in the 10-25% allele frequency range. Significantly, changes were inversely correlated with coverage indicating
high levels of sequencing artefacts were associated with samples with low amounts of available amplifiable template
due to fragmentation. The degree of fragmentation and sequencing artefacts differed between blocks sourced from
different anatomical pathology laboratories. In a limited validation of potentially actionable low frequency mutations, a
NRAS G12D mutation in a melanoma was shown to be a false positive.
Conclusions: These findings indicate that DNA damage following formalin fixation remains a major challenge in
laboratories working with MPS. Methodologies that assess, minimise or remove formalin-induced DNA damaged
templates as part of MPS protocols will aid in the interpretation of genomic results leading to better patient outcomes.* Correspondence: alex.dobrovic@ludwig.edu.au
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Advances in genomic technologies are improving the
capability to arrive at a more informed decision on how
to treat a patient [1,2]. In particular, a large number of
genes can be screened for actionable changes using mas-
sively parallel sequencing (MPS) approaches [3,4]. Ac-
curate and reliable interpretation of this new type of
genomic data is therefore critical in deciding the appro-
priate course of management for patients.
Most DNA for genetic testing from cancer patients is
extracted from formalin-fixed paraffin-embedded tumour
biopsies, where the primary intent is to preserve tumour
cellular structure for histological examination and diagno-
sis [5]. However, the formalin fixation process is detrimen-
tal to downstream genomic applications, causing issues,
such as DNA cross-linking to DNA and proteins, that can
stall polymerases and DNA-DNA crosslinks that can in-
hibit denaturation [6].
A common form of DNA damage induced by formalin
fixation is fragmentation, which can lead to low amounts
of amplifiable template for PCR amplification. Fragmen-
tation of DNA is caused by a number of factors during
the fixation process, e.g. low pH formalin over time in-
creases the rate of apurinic/apyrimidinic site formation
and eventually decomposition and fragmentation [7].
Long-term storage of formalin-fixed blocks can also in-
duce fragmentation due to exposure to environmental
conditions [8-10].
Another prominent type of DNA damage that occurs
commonly in formalin-fixed tissues is the hydrolytic de-
amination of cytosine to form uracil (or thymine if the
cytosine is methylated). This results in non-reproducible
C>T/G>A sequencing artefacts that are observed after
PCR amplification when using formalin-fixed and paraffin-
embedded (FFPE) DNA [11-13].
Recently, we assessed an amplicon-based MPS tech-
nology and showed that C>T and G>A changes were
the most prominent sequence errors in three formalin-
fixed lung squamous cell carcinoma samples [12]. While
such artefacts occur in many formalin-fixed samples, we
have found this to be more pronounced in highly frag-
mented samples. Due to stochastic effects, the low tem-
plate numbers increase the probability of occurrence of
template artefacts [14].
Many studies have reported the feasibility of using
DNA from formalin-fixed material using both conven-
tional PCR-based and MPS technologies [4,15,16]. Frag-
mentation can be a rate-limiting factor in amplicon-
based approaches especially those that use longer ampli-
cons. Shorter amplicons permit fragmented DNA from
formalin-fixed material to be used more successfully.
Some studies have reported elevated numbers of se-
quence artefacts [12,16-19] whereas others reported little
evidence of artefacts appearing in FFPE samples [15,20].The small number of samples assessed as well as the
varying age of biopsies, degree of fixation and sequen-
cing technologies used makes it difficult to know how
important sequence artefacts are as a source of error in
relatively fresh FFPE samples.
This study assessed the prevalence of DNA fragmenta-
tion and sequencing artefacts from a large cohort of
FFPE tumours using a uniform approach whereby all
blocks were of similar age, were extracted in the same
manner and were run through the same MPS platform.
The originating anatomical pathology laboratory was also
recorded to determine if variation in operating practices
could affect sequencing artefacts and DNA fragmentation.Methods
Patients and cell lines
Cancer 2015 is a large-scale, prospective, longitudinal,
multi-site cohort study of incident cancers in the Victorian
population. The aim of the Cancer 2015 study is to classify
cancers molecularly using MPS to promote more targeted
treatment of cancer patients and improve patient survival
and outcomes. An initial pilot phase was established to de-
termine the feasibility of adopting MPS for the diagnostic
mutational profiling of tumours. This study was approved
by the Human Research Ethics Committees at the Peter
MacCallum Cancer Centre, Royal Melbourne, Cabrini,
Geelong and Warrnambool Hospitals, all located within
the state of Victoria, Australia. All patients provided
informed consent to participate in this study. Formalin-
fixed, paraffin-embedded (FFPE) tumour blocks or un-
stained sections from FFPE tumour blocks were acquired
from anatomical pathology laboratories performing the
diagnosis and sent to the Peter MacCallum Cancer Centre
Pathology department. Epidemiological and clinical vari-
ables were collected from each patient. As controls repre-
senting good quality DNA, the cell lines NCI-H1975
(H1975) and HL-60 were also sequenced.DNA extraction
All blocks/sections were received at the Peter MacCallum
Cancer Centre Pathology department for DNA extraction.
The age of the blocks/sections was determined by identi-
fying the duration between the date of fixation (date of
surgery) and the date of extraction (arrival date at the
Peter MacCallum Cancer Centre). Up to ten unstained
tumour sections of 5 microns thickness were cut from
each block. DNA from FFPE sections and cell line samples
were extracted using the DNeasy blood and tissue kit
(Qiagen, Hilden, Germany) as per the manufacturer’s in-
structions. DNA quantification was performed using the
Qubit dsDNA HS Assay kit for the Qubit 2.0 Fluorometer
(Life Technologies, Carlsbad, CA). The Qubit readings
were used as a guideline for dilution of the DNA samples.
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FFPE derived DNA was checked for quality and concen-
tration using an 180 bp FTH1 TaqMan assay (Life Tech-
nologies). PCR was performed using the LightCycler 480
(Roche Diagnostics, Penzberg, Germany). The reaction
mixture included 1X TaqMan Gene Expression Master
Mix (Life Technologies), 1X FTH1 TaqMan Assay la-
beled with FAM (Life Technologies, # 4331182), 1 μL of
DNA and PCR grade water in a total volume of 11 μL.
PCR conditions included an activation step of 10 min at
95°C followed by 40 cycles of 95°C for 15 seconds and
annealing for 60 sec at 60°C. Based on a standard curve
generated from genomic DNA of known concentrations
of 50, 25, 12.5, 6.25, 3.13, 1.56 , 0.78 and 0.39 ng/μL and
copy numbers per μL of 16667, 8333, 4167, 2083, 1042,
521, 260, 130 respectively, the copy numbers per μL for
each sample were calculated according to the Light-
Cycler 480 software manufacturer’s instructions.
TruSeq amplicon cancer panel
The TruSeq Amplicon - Cancer Panel (TSACP) (Illumina,
San Diego, CA) comprises 212 amplicons from 48 genes
that are simultaneously amplified in a single-tube reaction.
We used 5 μL of each DNA sample (50 ng/μl) for the ex-
periment according to the manufacturer’s instructions.
We used the MiSeq system (Illumina) for paired end se-
quencing with a v2 150-bp kit.
Uracil-DNA glycosylase treatment
For samples treated with uracil-DNA glycosylase (UDG),
FFPE DNA was dispensed and reduced to a final volume
of 2 μL by vacuum centrifugation. The DNA was incubated
with 6.25 U (1 U/20 ng of DNA) UDG (New England
Biolabs, Ipswich, MA) in a final volume of 20 μL contain-
ing 1 U UDG buffer. After an initial incubation at 37°C for
2 h, the UDG enzyme was inactivated at 95°C for 10 min.
UDG-treated FFPE DNAs were stored at 4°C before use in
the TSACP reactions. Before use in sequencing, the vol-
ume of the reaction was reduced to a final volume of 5 μL
by vacuum centrifugation.
NRAS mutation testing
To confirm the NRAS negative result in sample Ca97, a
second MPS method using deep sequencing was also
used to assess exon 3 of the NRAS gene. Briefly, PCR
was performed on a Fluidigm Access Array according to
standard protocols [Access Array™ System for Illumina
Sequencing Platform User Guide (PN 100–3770)] with
the same FFPE sample (50 ng/μl) loaded into one well of
the Access Array. The primers were 5’-acactgacgacatgg
ttctacaGAGACAGGATCAGGTCAGCG-3’ and 5’-tacggt
agcagagacttggtctGATGTGGCTCGCCAATTAAC-3’, giv-
ing an amplicon size of 253 bp (CS1 and CS2 tags are
shown in lower case). After barcoding, the sample wasrun on an Illumina Miseq according to the manufac-
turer’s instructions (v2 150-bp kit).
Bioinformatics
CASAVA v1.8.2 was used to perform sample de-
multiplexing and to convert BCL files generated from
the MiSeq instrument into Fastq files containing short-
read data. Using the primer sequences that are present
in the data, short reads were first assigned to their respect-
ive amplicon. Global alignment based on the Needleman–
Wunsch algorithm was then performed between the reads
and the amplicon reference sequences to identify se-
quence variations. Likely true variants were identified by
a) VarScan2 and b) a variant frequency of >10% and were
not included in the analysis of sequencing artefacts. Vari-
ants with a frequency < 1% were assumed to be sequen-
cing errors. The remaining base changes (i.e. all except
true biological variants and sequencing errors) were
counted and categorised into respective nucleotide groups
using custom Python scripts. In addition to the 1-10% al-
lele frequency range, the same pipeline was also used to
determine artefacts in the 10-25% allele frequency range.
Statistical analysis
Spearman tests were used to examine associations be-
tween continuous variables. The Kruskal–Wallis one-
way analysis of variance followed by the Dunn’s post hoc
test was used to test for associations between continuous
variables (C>T/G>A changes, FTH1 results) versus ana-
tomical pathology laboratory and tumour type. All ana-
lyses were performed using GraphPad Prism software
version 6.01.
Results
Cell lines and FFPE samples
This study used the data from the first 488 patients re-
cruited from the pilot phase of the Cancer 2015 study
(Table 1). The FFPE samples analysed in this study were
relatively recent (median: 77 days, mean: 93.4 ± 77 days)
with a range of 4 to 851 days post fixation (Additional
file 1: Table S1). HL-60 cell line DNA was used in each
sequencing run and allowed run-to-run differences to be
compared in terms of coverage and sequencing artefacts.
Assessment of fragmentation in FFPE samples
The quality and quantity of DNA extracted from tumour
biopsies can vary substantially between samples. DNA
fragmentation is a major form of DNA damage that can
be assessed through a number of quality control assays
that measure if a minimal length of template can be
amplified. Part of the pilot phase of the Cancer 2015
study was to assess the feasibility of using FFPE DNA
for multiple parallel sequencing using the TSACP assay.
The average length of amplicons in the assay is ~175 bp
Table 1 Summary of formalin-fixed samples
Tumour type Number of cases Percentage
Breast 81 16.6%






Bone and soft tissue 22 4.5%
Oesophagogastric 15 3.1%
Renal 14 2.9%
Central nervous system 12 2.5%
Melanoma 11 2.3%
Cancer of unknown primary 8 1.6%
*Represents other cancer types with smaller numbers including pancreatic,
ovarian, thyroid, testicular, bladder, hepatic, endometrial, biliary and anal cancers.
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assessed for amplifiable copy numbers using the
commercially available Taqman assay that measures
the copies of the FTH1 sequence per microlitre of a
sample based on the amplification of an 180 bp product.
As expected, FFPE samples showed a large spectrum in
the estimated number of copies of the FTH1 sequence
(Figure 1 and Additional file 1: Table S1). The cell line
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Figure 1 Association of fragmentation of DNA in FFPE samples with l
reads) versus the copies of the FTH1 gene as assessed by a Taqman PCR as
between the FTH1 result and coverage (Spearman correlation, r = −0.29, p < 0
allele frequency range are shown in red.FTH1 assay (mean copies per microlitre were 152 and
160 for the HL-60 and H-1975 cell lines respectively at
50 ng/μl).
Overall total coverage of a sample after sequencing
would be expected to be inversely associated with the
amount of fragmentation whereby samples with high
level of DNA fragmentation would have less amplifica-
tion and therefore associated with lower coverage. By
comparing both the FTH1 and coverage results for all
FFPE samples, there was a weak but significant associ-
ation between these two variables (r = 0.29, p < 0.0001,
Spearman Rank correlation). Given a minimum of
200,000 total reads to achieve a mean of ~1000X across
all amplicons in a sample, 55/488 samples would not
achieved this level of coverage.
There were two outlier samples that displayed high
amounts of amplifiable template as measured by the
FTH1 assay but resulted in low coverage (samples Ca23
and Ca156). These samples however could have low
coverage because of experimental error during the pro-
cessing of the sample resulting in low coverage. How-
ever, for the overwhelming majority of other samples,
there was a noticeable trend with the degree of frag-
mentation as measured by the FTH1 assay and the
resulting coverage after sequencing. Importantly, this
indicates that significant fragmentation is present even
in relatively recently fixed biopsies and is an important
factor leading to lower amounts of successful sequen-
cing data.er microlitre 
250 300 350 400 450
ow sequencing coverage. Coverage of each sample (number of
say (copies per microlitre). n = 253. There was a positive correlation
.0001). The 50 samples with the highest C>T/G>A levels in the 1-10%
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While fragmentation is a well known form of DNA dam-
age that is present in a large number of FFPE samples,
sequencing artefacts as a result of PCR amplification
have not been extensively studied, especially in relatively
recent samples as would be used diagnostically.
Hence, our next analysis was to determine if sequence
artefacts were also present in our cohort of recently fixed
samples. We previously published an informatic pipeline to
assess the level of artefacts in archival lung squamous cell
carcinoma samples [12]. This pipeline identifies counts of
nucleotide changes within the 1-10% frequency range and
removes counts from likely true mutations that are identi-
fied through the Varscan2 caller. Using this pipeline, we
measured the degree of artefacts between the 1-10% range
for all 488 FFPE samples and cell line samples.
The results of the cell line samples are shown in
Figure 2A (zoomed view) and illustrate no dramatic
C>T/G>A changes observed at this 1-10% allele fre-
quency range. There was however a consistently higher
rate of C>T/G>A changes in the H1975 cell line com-
pared to the HL-60 cell line suggesting low level hetero-
geneity that was not removed by the pipeline. Coverage
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Figure 2 Significant levels of C>T/G>A sequencing artefacts in FFPE s
FFPE samples. The prevalence of each type of nucleotide change in the 1-1
through the Varscan2 variant caller were operationally removed to enrich f
sorted according to the counts of C>T/G>A changes. Zoomed view: HL-60
prevalence of each type of nucleotide change in the 10-25% allele frequen
counts of C>T/G>A changes.and quite similar between runs [mean 52 million reads ±
13 million reads (standard deviation), n = 12]. Counts for
sequencing artefacts were also very low and consistent.
This indicates no major run-to-run bias.
In contrast, the FFPE samples showed a large range of
C>T/G>A changes in a large proportion of samples
(Figure 2). The increase in C>T/G>A changes was not
discrete and not confined to only a subset of samples but
appeared to be continuous suggesting that this type of
artefact is ubiquitous in nature and will occur to some ex-
tent in every FFPE sample. The relative proportion of
C>T/G>A changes was highly significant compared to
other nucleotide changes (p < 0.0001, Kruskal–Wallis one-
way analysis of variance) and formed 32% of all nucleotide
changes overall, a proportion that was double what was
expected due to chance.
By contrast, the same analysis, applied to look at possible
artefacts between the 10-25% allele frequency range, indi-
cated that C>T/G>A changes appear at much lower levels
compared to the 1-10% allele frequency range (the scale
on the y axis of Figure 2B is much smaller than that of 2A)
and most likely represent real variants that were not be
removed using our algorithm. Importantly, there was no

























amples. (A) Assessment of sequence artefacts in cell line DNA and
0% allele frequency range was computed. Likely true variants identified
or sequencing artefact changes. The graph shows all FFPE samples
and H1975 cell lines were used as good quality DNA controls. (B) The
cy range. The graph shows all FFPE samples sorted according to the
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DNA that would display little or no artefacts, the me-
dian C>T/G>A change count in the 1-10% allele fre-
quency range was 272 contrasting to a much more
higher median C>T/G>A count in FFPE samples of
1515. These findings not only confirm our original find-
ings that C>T/G>A are the most predominant type of
sequencing artefact but also indicate that they occur in
all FFPE samples to some degree.
Correlation of sequence artefacts with coverage
An interesting observation in samples with high C>T/
G>A changes in the 1-10% range was a parallel increase
in the number of other nucleotide changes. This could
be due to the stochastic nature of low template samples
which increase the probability for not only C>T/G>A ar-
tefacts but also other nucleotide artefacts to appear.
To confirm this phenomenon, the coverage and counts
for C>T/G>A changes were graphed for each FFPE sam-
ple (Figure 3). As expected, there was a significant asso-
ciation between low coverage and high amounts of C>T/
G>A changes in the 1-10% allele frequency range (r =
−0.24, p < 0.0001, Spearman Rank correlation). This is also
in line with the fragmentation measurements with the 50
samples with the highest C>T/G>A levels strongly trend-
ing towards having lower estimated template numbers in
the FTH1 assay (Figure 1). This indicates that despite the
same amount of DNA used for each sample that the re-
duction of available templates caused by fragmentation
can lead to a higher probability for sequence artefacts to
be observed after PCR amplification.
Correlation of anatomical laboratory with sequence
artefacts and coverage
While DNA was extracted at the same location with the















































Figure 3 Low coverage samples have higher rates of C>T/G>A seque
(blue) and the counts of C>T/G>A sequencing artefacts (red) are plotted o
and C>T/G>A sequence artefacts (Spearman correlation, r = −0.24, p < 0.00paraffin embedded in different anatomical pathology la-
boratories across Victoria, Australia. Since different ana-
tomical laboratories might have different practices
regarding the fixation of tissues, we examined DNA dam-
age in relation to the originating anatomical laboratory.
There was a significant difference for both fragmentation
and sequence artefacts between anatomical pathology
(AP) laboratories (p < 0.0001, Kruskal-Wallis test). Dunn’s
Multiple Comparison test indicated significant difference
between AP7 versus AP22 and AP26 for fragmentation
analysis, and AP7 versus AP22 for sequencing artefacts
(Additional file 2: Figure S1). Despite standardization,
these results suggest that fixation processes may vary
across different labs. The age of the blocks or the tumour
type was not significantly correlated with the degree of
fragmentation or sequence artefacts.
Case studies: samples with potential false positive clinical
mutation calls
To determine if samples with high artefacts contain mu-
tations that mimic actionable mutations, we selectively ex-
amined the variant calls from samples with high artefact
rates. From this, we found three samples that had action-
able mutations with low frequencies and with enough
available DNA for further testing. We treated these sam-
ples with uracil-DNA glycosylase (UDG), sequenced them
using the TSACP and then examined if the mutation was
still present. As shown in Figure 4, PIK3CA mutations in
the two breast cancer cases (Ca309 and Ca285) were con-
firmed to be real mutations as the identical mutation of
similar frequency was identified in each of these cases
after UDG treatment. PIK3CA mutations are positive
prognostic factors in breast cancer [21,22], supporting the
clinical utility of MPS for the detection of clinically action-
able mutations. It also illustrates that this platform can de-
tect real mutations even at low frequencies.ncing artefacts. For all FFPE samples (x-axis), values for coverage
n the same y-axis. There was an inverse correlation between coverage
01).
Figure 4 Uracil-DNA glycosylase treatment of FFPE DNA samples distinguishes true and false positive clinical relevant mutations.
Integrative Genomic Viewer (IGV) screenshots of two breast cancers and one melanoma sample pre- and post- uracil-DNA glycosylase (UDG)
treatment samples. The two breast cancer samples have confirmed PIK3CA mutations (E545K for Ca309 and H1047Y for Ca285) as these mutations
were still detected after UDG treatment. The NRAS G12D mutation identified in the pre-UDG sample (Ca97) was a false positive as it was not
present after UDG treatment. The variant reads over the total reads and overall allele frequency (a.f.) are shown for each case.
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c.35 G>A, p.G12D mutation (Ca97), resequencing (after
UDG treatment) using the TSACP platform did not con-
firm the same mutation. To further validate this result,
the sample was tested by an orthogonal MPS method
(Fluidigm Access Array microfluidic chip system) that
covers the NRAS exon 2 region at extremely high cover-
age (Additional file 2: Figure S2). This method also could
not detect the mutation suggesting that the original call
for the mutation was a false positive.
Discussion
While the implementation of MPS into a clinical setting
is currently in progress in numerous laboratories world-
wide, there are still a number of challenges using DNA
from FFPE cancer specimens for this application. The
prevalence of DNA damage associated with formalin fix-
ation in clinical material has not been extensively stud-
ied, particular in terms of cancer genomics. Most
genomic studies dealing with FFPE DNA are relatively
small in numbers with the archival status of specimens
in most cases remaining unknown [4,16]. In contrast,
this study had a relatively narrow window in which sam-
ples were formalin-fixed and had a standardised and
centralised point of DNA extraction and sequencing.
FFPE samples in this study therefore accurately repre-
sent those that would enter a molecular diagnostic clin-
ical workflow.
To our knowledge, this study represents the largest as-
sessment of formalin induced fragmentation and sequen-
cing artefacts using clinical FFPE samples. From our set
of analyses, we have confirmed that both fragmentation
and sequencing artefacts are common forms of DNA
damage from formalin-fixed material even if blocks arerelatively new. As a result, this work illustrates these
forms of DNA damage can have major consequences for
downstream interpretation as not all actionable muta-
tions could be validated.
There are a limited number of publications highlight-
ing the ability of amplicon-based MPS to identify clinic-
ally relevant mutations or canonical mutations from
DNA obtained from various tumour types [23-26]. How-
ever, these studies looked at a relatively small number of
cases, usually reported only canonical mutations, and
where validation of variants was performed, demon-
strated variation in the results obtained. For example, in
the study investigating the sensitivity of immunohisto-
chemistry (IHC) versus Sanger sequencing to BRAF
V600E mutations in FFPE derived DNA from papillary
thyroid carcinoma specimens, Bullock and colleagues
utilised the TSACP as an alternative sequencing plat-
form [23]. The TSACP was able to identify the BRAF
V600E mutation in three out of 11 IHC positive cases
with variant frequencies of 10-32%, which Sanger se-
quencing failed to detect. When DNA was then macro-
dissected from the same tumour blocks, both sequencing
and the TSACP analyses could now both detect the
V600E mutation in seven cases (7/11). This confirms
that the platform is comparatively more sensitive than
the “gold standard” of Sanger sequencing for low fre-
quency mutations.
In this study we explored two common form of DNA
damage caused by formalin, i.e. fragmentation and se-
quencing artefacts. Assessment of fragmentation was
performed using a copy number assessment PCR prior
to MPS. The weak association between total coverage
counts and the FTH1 results could be explained by the
limitations of the FTH1 assay. While the assay can
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gree of fragmentation, the assay is designed only around
a product of 180 bp and for only one locus. Conse-
quently, the FTH1 assay cannot accurately assess the en-
tire range of product sizes generated by the TSACP
protocol. Testing multiple loci across various fragment
lengths is therefore recommended for FFPE samples in
MPS testing to predict poor quality amplifiable DNA [27].
Interestingly, the degree of C>T/G>A artefacts forms a
continuum suggesting that the source of DNA damage
causing these changes occurs to some degree in every
sample. Procedurally, although the practice of fixation of
tumour specimens is standardised, the observation that
samples processed from one anatomical pathology la-
boratory (AP7) had a significantly higher rate of sequen-
cing artefacts and fragmentation indicates that fixation
processes may not actually be uniform between different
laboratories.
Assessment of other variables potentially involved in
DNA damage such as the duration of transport from pa-
tient to the anatomical pathology laboratory, and size of












Figure 5 Low template copies are associated with higher probability
DNA from sources such as blood and fresh frozen tissue, fragmentation an
amounts of amplifiable template increase the likelihood of accurately ident
stochastic enrichment of sequencing artefacts. In FFPE DNA with moderate
some formalin-induced uracil lesions being present in template DNA. Subseq
template numbers. Uracil lesions are also amplified, and due to the lower cop
G>A changes). These artefacts will be low in frequency. In the case of FFPE w
are severely limited. An artefact in one of these templates can then appear as
subsequently be interpreted as real mutations.study. In addition, the degree and spectrum of DNA
damage from a formalin-fixed sample depends on envir-
onmental factors such as exposure to heat, light and the
concentration and age of formalin used for fixation. The
age of blocks examined is another consideration as long-
term storage in suboptimal environments can cause sig-
nificant DNA damage. Further dissection of these factors
in a more controlled setting will provide significant ben-
efits to the preservation of DNA for subsequent testing.
Another consideration is the type of polymerase used
in this study. While the type of polymerase used in the
TSACP was not disclosed due to commercial reasons it
is probably not proofreading since proofreading enzymes
are known to stall at uracil lesions and in effect, replicate
the effect of UDG treatment. Further examination of
polymerases which increase correct sequence amplifica-
tion but still maintain sufficient amplification for se-
quencing are required.
There is a possibility that some changes within the 1-
10% allele frequency do represent low-level heterogen-
eity and were not detected by the Varscan2 variant caller
and removed from our analysis of sequencing artefacts.ost-amplification Result Legend
of sequencing artefacts post-PCR amplification. In good quality
d uracil lesions are present at very low levels. In this circumstance, high
ifying mutations due to high sequencing coverage with little or no
fragmentation, the number of amplifiable templates is reduced, with
uently PCR amplification results in lower coverage due to less amplifiable
y numbers, can appear as non-reproducible sequencing artefacts (C>T/
ith high amounts of fragmentation, the numbers of amplifiable template
a moderate to high frequency sequencing variant. These can
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this assessment but were not available for this study to
confirm this.
In this study, we confirmed the detection of two low
frequency actionable mutations in the PIK3CA gene, in
breast carcinoma cases. These mutations remained after
the sequencing was repeated (and after UDG treatment).
Given the clinical context of these mutations in breast
cancer, these mutations are of potential clinical benefit
to the patient that may have implications for PIK3CA in-
hibitors that target the PI3K/AKT/mTOR pathway
[21,22]. It also illustrates that this platform can detect
real mutations even at low frequencies.
In contrast, an activating NRAS G12D mutation dis-
covered originally in our first screen but not confirmed
in the same DNA specimen by subsequent UDG treat-
ment or MPS has major implications for the patient. Ac-
tivating mutations in NRAS have been reported in
approximately 20% of all melanomas [28] and are poten-
tially sensitive to therapeutics that target downstream
signaling through mitogen-activated protein kinase kin-
ase and phosphatidylinositol 3-OH kinase or AKT
[29,30]. This is a clear demonstration of the dangers that
can arise from MPS data without proper validation.
Complete validation of all variants was not possible in
this study because of the extremely large number of var-
iants detected and the lack of remaining DNA available
for all samples. Undoubtedly a large number of these
variants will be false positives, especially in the 1-10% al-
lele frequency range. While validation of every variant is
a laborious task costing time, material and expense, we
recommend that validation of actionable mutations that
will directly affect patient management be performed in
this kind of testing. We also propose that quality control
measures be adopted prior to sequencing including the
implementation of more efficient and accurate quality
control assays that evaluate DNA concentration, frag-
mentation and the presence of uracil lesions.
While we have shown treatment with UDG is effective
in reducing artefactual variants, there are a number of
other strategies to minimise artefacts occurring, particu-
larly those using non-capture based-technologies [31].
This includes performing duplicate reactions for the
same sample or through internal validation by having
overlapping amplicons covering the same loci (as is the
case in the newer TruSight™ version of the TSACP panel
that was released after this study was concluded).
Conclusions
DNA damage caused by formalin fixation appears to be
very common even in relatively recent samples. This
study demonstrates that higher amounts of fragmenta-
tion will increase the probability of higher rates of se-
quencing artefacts. This is summarised in Figure 5. Thefindings from this study not only have implications for
MPS-based platforms but also conventional PCR-based
methodologies which commonly use FFPE DNA as an
input such as HRM and Sanger sequencing. Samples
with a high degree of DNA damage must be treated with
caution as potential false positives that can arise from
formalin damage may have major consequences for
downstream clinical decisions. As MPS becomes in-
creasingly incorporated into clinical diagnostic work-
flows, it is important to assess DNA damage caused by
formalin fixation, as this will greatly optimise diagnostic
workflows, increase accuracy of results and lead to bet-
ter outcomes for patients.
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